Current Report Filing (8-k)
November 18 2020 - 1:25PM
Edgar (US Regulatory)
0001410098
false
0001410098
2020-11-18
2020-11-18
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d)
of
the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): November 18, 2020
CORMEDIX
INC.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
001-34673
|
|
20-5894890
|
(State
of other jurisdiction of
incorporation or organization)
|
|
(Commission
File Number)
|
|
(I.R.S.
Employer
Identification No.)
|
300
Connell Drive, Suite 4200
Berkeley Heights, NJ
|
|
07922
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: (908) 517-9500
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2, below):
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Exchange Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
Common
stock, $0.001 par value
|
|
CRMD
|
|
NYSE
American LLC
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
8.01. Other Events.
On
November 18, 2020, CorMedix Inc. (the “Company”) issued a press release to announce that the U.S. Food and Drug Administration
(the “FDA”) has decided to cancel the Antimicrobial Drug Advisory Committee meeting tentatively scheduled for January
14, 2021 to discuss the New Drug Application for Defencath™ after determining that discussion at an advisory committee is
not needed. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein
by reference.
Item
9.01. Financial Statements and Exhibits.
(d)
Exhibits
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
CORMEDIX
INC.
|
|
|
|
Date:
November 18, 2020
|
By:
|
/s/
Khoso Baluch
|
|
Name:
|
Khoso
Baluch
|
|
Title:
|
Chief
Executive Officer
|
2
CorMedix (AMEX:CRMD)
Historical Stock Chart
From Aug 2024 to Sep 2024
CorMedix (AMEX:CRMD)
Historical Stock Chart
From Sep 2023 to Sep 2024